Here's why the ResMed share price is charging higher today

ResMed shares have been given a boost…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc (ASX: RMD) share price has been a positive performer on Thursday.

In morning trade, the sleep treatment company's shares are up almost 2% to $34.08.

This means the ResMed share price is now up 20% over the last two months.

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.

Image source: Getty Images

What's driving the ResMed share price higher?

Investors have been buying the company's shares today following a strong night for its NYSE-listed shares.

ResMed's shares rose almost 5% on Wall Street last night after the US FDA issued a recall for rival Philips' masks used with bilevel positive airway pressure machines and continuous positive airway pressure (CPAP) machines.

The regulator notes that the recalled mask can cause potential injuries or death when use with magnets interferes with certain implanted metallic medical devices and metallic objects in the body. Worryingly, it isn't just the user of the mask that is at risk. The FDA statement explains:

The recalled masks have magnets (placements shown by black circles in the picture below) and can cause potential injuries or death when use of a recalled mask with magnets interferes with certain implanted metallic medical devices and metallic objects in the body. These potential adverse events can occur in people who use the masks, or in people near a person using the mask. Additionally, the recalled Philips masks may be used with other manufacturers' BiPAP and CPAP machines.

Broker responds to the news

A number of brokers have responded positively to this news, giving the ResMed share price an additional boost.

Credit Suisse and Macquarie have both released bullish notes suggesting that this could lead to market share gains for ResMed.

In response, Macquarie has retained its outperform rating and $38.70 price target and Credit Suisse has retained its outperform rating with a $40.00 price target.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 healthcare shares to buy amid sector rout

The experts are backing these stocks for price growth.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

Are investors taking a big gamble chasing 4DX shares higher and higher?

Investor interest in this ASX healthcare tech stock is booming.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »